Ocuphire Pharma Investor Presentation Deck

Global Partnership with Viatris for Nyxol Viatris Has Selected Nyxol to be a Key Element of its Global Eye Care Division Ocuphire Partner for Nyxol global commercialization Fully funded development and commercialization costs for all 3 Nyxol indications Allows Ocuphire to focus on APX3330 development Strengthens cash position into 2025 > $35 million upfront ➤ Funding for potentially all R&D and commercialization for all 3 indications globally $130 million in regulatory and sales milestones ➤ First potential $10 million milestone payment on FDA approval in RM ➤ Tiered double digit royalties through 2040 32

View entire presentation